Reported Earnings • Apr 28
First quarter 2026 earnings released: EPS: kr0.17 (vs kr1.24 loss in 1Q 2025) First quarter 2026 results: EPS: kr0.17 (up from kr1.24 loss in 1Q 2025). Revenue: kr61.8m (up 13% from 1Q 2025). Net income: kr2.90m (up kr23.4m from 1Q 2025). Profit margin: 4.7% (up from net loss in 1Q 2025). The move to profitability was primarily driven by lower expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. New Risk • Apr 10
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr62m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. This is currently the only risk that has been identified for the company. Duyuru • Apr 03
Devyser Diagnostics AB (publ), Annual General Meeting, May 06, 2026 Devyser Diagnostics AB (publ), Annual General Meeting, May 06, 2026, at 11:00 W. Europe Standard Time. Location: branningevagen 12, 120 54 arsta, Sweden Reported Earnings • Mar 30
Full year 2025 earnings released: kr0.51 loss per share (vs kr3.75 loss in FY 2024) Full year 2025 results: kr0.51 loss per share (improved from kr3.75 loss in FY 2024). Revenue: kr250.5m (up 16% from FY 2024). Net loss: kr8.40m (loss narrowed 86% from FY 2024). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 13
Full year 2025 earnings released: kr0.51 loss per share (vs kr3.75 loss in FY 2024) Full year 2025 results: kr0.51 loss per share (improved from kr3.75 loss in FY 2024). Revenue: kr250.5m (up 16% from FY 2024). Net loss: kr8.40m (loss narrowed 86% from FY 2024). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 16% per year. Recent Insider Transactions • Nov 13
Chairman recently bought €141k worth of stock On the 7th of November, Mia Arnhult bought around 14k shares on-market at roughly €10.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Mia has been a buyer over the last 12 months, purchasing a net total of €208k worth in shares. Reported Earnings • Nov 06
Third quarter 2025 earnings released: kr0.17 loss per share (vs kr1.41 loss in 3Q 2024) Third quarter 2025 results: kr0.17 loss per share (improved from kr1.41 loss in 3Q 2024). Revenue: kr56.4m (up 16% from 3Q 2024). Net loss: kr2.80m (loss narrowed 88% from 3Q 2024). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 15% per year, which means it is tracking significantly ahead of earnings growth. Buy Or Sell Opportunity • Nov 04
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 17% to €11.04. The fair value is estimated to be €14.43, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has declined by 8.6%. Reported Earnings • Jul 22
Second quarter 2025 earnings released: EPS: kr0.079 (vs kr1.41 loss in 2Q 2024) Second quarter 2025 results: EPS: kr0.079 (up from kr1.41 loss in 2Q 2024). Revenue: kr67.4m (up 27% from 2Q 2024). Net income: kr1.30m (up kr24.2m from 2Q 2024). Profit margin: 1.9% (up from net loss in 2Q 2024). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings. Duyuru • Jun 30
Devyser Launches Genomic Blood Typing Assay Devyser announced the global launch of, a next-Devyser Genomic Blood Typing generation sequencing (NGS)-based solution that redefines molecular blood group research. Developed exclusively, this all-in-one assay enables comprehensive genetic blood typing-covering red blood cell (RBC), human platelet antigen (HPA), and human neutrophil antigen (HNA) systems-in a single, streamlined test. Designed to address the complexities of blood group analysis in transfusion and transplantation research, Devyser Genomic Blood Typed offers high-resolution results with unprecedented workflow simplicity and software-guided interpretation. Simplifying complexity in blood group research. Traditional serological methods often struggle with weak antigen expression, rare variants, or ambiguous results-particularly across diverse ethnic backgrounds. Devyser Genomic Blood typing fills these gaps by delivering clear and accurate insights into blood antigen profiles at the genetic level. Advancing molecular blood typing in research settings. Devyser Genomic blood typing empowers research laboratories, transfusion centers, and transplant programs to move beyond the limitations of serology. Whether identifying rare blood types or studying immune compatibility, the solution offers precision and reproducibility that elevate scientific confidence. New Risk • Jun 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Apr 07
Full year 2024 earnings released: kr3.75 loss per share (vs kr3.31 loss in FY 2023) Full year 2024 results: kr3.75 loss per share (further deteriorated from kr3.31 loss in FY 2023). Revenue: kr216.9m (up 28% from FY 2023). Net loss: kr61.5m (loss widened 15% from FY 2023). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Reported Earnings • Feb 14
Full year 2024 earnings released: kr3.75 loss per share (vs kr3.31 loss in FY 2023) Full year 2024 results: kr3.75 loss per share (further deteriorated from kr3.31 loss in FY 2023). Revenue: kr216.9m (up 28% from FY 2023). Net loss: kr61.5m (loss widened 15% from FY 2023). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Duyuru • Feb 04
Devyser Launches A New Updated NGS Assay to Simplify Thalassemia Testing Devyser has launched Devyser Thalassemia v2, a next-generation sequencing (NGS) solution designed to further simplify genetic testing. The improved technology, will help broader screening for thalassemia with greater precision in detecting structural variants, saving time and ensuring better results for researchers worldwide. This product will allow laboratories to achieve rapid, comprehensive results, reducing workflow complexity and enabling efficient genetic profiling through a single assay. Devyser Thalassemia v2 offers a streamlined protocol with minimal hands-on time, empowering labs to deliver reliable and reproducible results consistently. Devyser Thalassemia v2 is currently available globally as a Research Use Only (RUO) product. Board Change • Jan 17
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Thomas Eklund was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Jan 16
Devyser Diagnostics Announces CEO Changes Devyser Diagnostics announced Fredrik Alpsten and the Board of Directors have now reached an agreement that he will leave his position as CEO of Devyser. Devyser's Board of Directors has initiated the recruitment of a new CEO. Fredrik Dahl, PhD in Molecular Medicine, currently a board member and well acquainted with the company, has been appointed acting CEO. Fredrik Dahl holds a PhD in Molecular Medicine from Uppsala University and has done research at Stanford University in DNA technology. After his studies at Stanford, Fredrik worked in California at a pioneering research company in DNA sequencing. Thereafter he moved back to Sweden and co-founded Halo Genomics, which was sold to the American Agilent Technologies, and co-founded Vanadis Diagnostics, which was sold to the American diagnostics company PerkinElmer (now Revvity). Fredrik Dahl thus has extensive international experience in various management roles from global research and diagnostics companies. Fredrik Dahl will remain as a member of Devyser's Board of Directors. Duyuru • Dec 02
Devyser Achieves Class D IVDR Approval for its RHD Product Devyser has received IVDR approval for its non-invasive fetal RHD screening product. This marks the first approval of a Class D product, the highest risk class under the new, comprehensive European regulation that came into force in May 2022. This approval confirms that Devyser's RHD product meets the stringent safety, efficacy, and quality requirements. Devyser RHD is a highly sensitive CE-IVD labelled QPCR test to conduct accurate non-invasive screening for fetal RHD that helps clinicians avoid untargeted and unnecessary treatment. Duyuru • Nov 02
Devyser Diagnostics AB (publ), Annual General Meeting, May 14, 2025 Devyser Diagnostics AB (publ), Annual General Meeting, May 14, 2025. Reported Earnings • Nov 01
Third quarter 2024 earnings released: kr1.41 loss per share (vs kr0.37 loss in 3Q 2023) Third quarter 2024 results: kr1.41 loss per share (further deteriorated from kr0.37 loss in 3Q 2023). Revenue: kr48.7m (up 4.3% from 3Q 2023). Net loss: kr23.2m (loss widened 287% from 3Q 2023). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. New Risk • Oct 22
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Reported Earnings • Jul 24
Second quarter 2024 earnings released: kr1.41 loss per share (vs kr0.90 loss in 2Q 2023) Second quarter 2024 results: kr1.41 loss per share (further deteriorated from kr0.90 loss in 2Q 2023). Revenue: kr53.2m (up 41% from 2Q 2023). Net loss: kr22.9m (loss widened 57% from 2Q 2023). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Europe. New Risk • Jul 07
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Recent Insider Transactions • Jun 23
Chief Executive Officer recently sold €495k worth of stock On the 19th of June, Fredrik Alpsten sold around 51k shares on-market at roughly €9.71 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Fredrik has been a net seller over the last 12 months, reducing personal holdings by €19k. Duyuru • May 15
Devyser Diagnostics AB (publ) Appoints Thomas Eklund as Member of the Board of Directors Devyser Diagnostics AB (publ) announced that at the Annual General Meeting held on 14 May 2024 Thomas Eklund was elected as new member of the Board of Directors for the same period. Duyuru • Apr 26
Devyser Receives IVDR Approval for Post-Transplant Monitoring Software Devyser has received IVDR approval for Advyser Solid organs, its software for the post-transplant product One Lambda Devyser Accept cfDNA. This is Devyser's first European approval for post-transplant monitoring software under the new, more comprehensive IVD regulation that came into force in May 2022, and it confirms Devyser software meets the established safety, efficacy, and quality requirements. Advyser Solid organs is an IVD software for monitoring donor-derived cell-free DNA (dd-cfDNA) in patients following kidney transplantation. The software is intended for use with One Lambda Devyser accept cfDNA, a novel NGS test for detecting dd-cfDNA in blood samples from kidney transplant patients. The assay received IVDR approval in 2023. The product mentioned is CE-IVD marketed but not FDA-cleared. Availability in each country depends on local regulatory marketing authorization status. Reported Earnings • Apr 14
Full year 2023 earnings released: kr3.31 loss per share (vs kr2.89 loss in FY 2022) Full year 2023 results: kr3.31 loss per share (further deteriorated from kr2.89 loss in FY 2022). Revenue: kr169.3m (up 34% from FY 2022). Net loss: kr53.6m (loss widened 17% from FY 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Duyuru • Feb 29
Devyser Diagnostics AB (publ) Announces Study Publication Demonstrating dd-cfDNA Detection in Dual Donor Kidney Transplant Patient Devyser Diagnostics AB (publ) announced an article titled "Detection of donor- derived cell-free DNA (dd-cfDNA) in the setting of multiple kidney transplantations" was published in the journal, Frontiers in Immunology. This study was done in collaboration with the Departments of Immunology and Nephrology at the University of Zurich, including Dr. Jakob Nilsson using the One Lambda Devyser Accept cfDNA assay. This is the first report on the use of an NGS assay to detect dd-cfDNA from multiple kidney transplants to monitor organ damage following transplantation. dd-cfDNA is used as a marker for monitoring organ damage and rejection following transplantation. Successfully differentiating dd-cfDNA in patients who have received a dual donor kidney transplant, or a sequential transplant, is a significant challenge in the accurate monitoring of such patients. This study showed that transplant patients had detectable cfDNA from multiple donor grafts and One Lambda Devyser Accept cfDNA was able to maintain a high sensitivity. The authors concluded that the results have the potential to influence clinical decision-making. Reported Earnings • Feb 22
Full year 2023 earnings released: kr3.31 loss per share (vs kr2.89 loss in FY 2022) Full year 2023 results: kr3.31 loss per share (further deteriorated from kr2.89 loss in FY 2022). Revenue: kr169.3m (up 34% from FY 2022). Net loss: kr53.6m (loss widened 17% from FY 2022). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Duyuru • Jan 29
Devyser Diagnostics AB (Publ) Announces Michael Uhlin, CSO Joins Management Team as of February 1, 2024 Devyser Diagnostics AB (publ) announcing the strengthening and expanding of its management team as of February 1, 2024. Michael Uhlin, who has been Devyser’s CSO since the fall of 2023, will join the management team, with responsibility for development/innovation, including bioinformatics, clinical affairs and Devyser Genomic Laboratories, Devyser’s CLIA-certified laboratory. He will report to Devyser’s CEO, Fredrik Alpsten. Michael Uhlin, who also holds a professorship at Karolinska Institutet, has solid experience in the global life sciences sector, in both academia and industry, where he has held various senior positions. He has long been engaged in translational research and development in areas relevant to Devyser’s activities. Duyuru • Jan 12
Devyser Diagnostics AB (publ) to Report Fiscal Year 2023 Final Results on Apr 11, 2024 Devyser Diagnostics AB (publ) announced that they will report fiscal year 2023 final results at 9:00 AM, Central European Standard Time on Apr 11, 2024 New Risk • Nov 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Recent Insider Transactions • Nov 17
Chief Executive Officer recently bought €130k worth of stock On the 10th of November, Fredrik Alpsten bought around 25k shares on-market at roughly €5.18 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Fredrik has been a buyer over the last 12 months, purchasing a net total of €33k worth in shares. Reported Earnings • Nov 10
Third quarter 2023 earnings released: kr0.37 loss per share (vs kr0.55 loss in 3Q 2022) Third quarter 2023 results: kr0.37 loss per share (improved from kr0.55 loss in 3Q 2022). Revenue: kr46.7m (up 50% from 3Q 2022). Net loss: kr6.00m (loss narrowed 32% from 3Q 2022). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Duyuru • Nov 09
Devyser Diagnostics AB (publ), Annual General Meeting, May 14, 2024 Devyser Diagnostics AB (publ), Annual General Meeting, May 14, 2024. Recent Insider Transactions • Sep 03
Independent Director recently bought €92k worth of stock On the 31st of August, Fredrik Dahl bought around 15k shares on-market at roughly €6.14 per share. This transaction amounted to 78% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €104k more in shares than they have sold in the last 12 months. New Risk • Aug 25
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr60m Forecast net loss in 2 years: kr1.7m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company. Reported Earnings • Aug 23
Second quarter 2023 earnings released: kr0.90 loss per share (vs kr0.90 loss in 2Q 2022) Second quarter 2023 results: kr0.90 loss per share (further deteriorated from kr0.90 loss in 2Q 2022). Revenue: kr37.7m (up 22% from 2Q 2022). Net loss: kr14.6m (loss widened 2.1% from 2Q 2022). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Duyuru • Nov 11
Devyser Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024 Devyser Diagnostics AB (publ) announced that they will report fiscal year 2023 results on Feb 20, 2024